AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) shares fell 1.3% during mid-day trading on Tuesday . The stock traded as low as $25.89 and last traded at $26.03, with a volume of 261,064 shares changing hands. The stock had previously closed at $26.37.

Several brokerages have recently issued reports on AMAG. Raymond James Financial Inc. cut shares of AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 4th. Zacks Investment Research cut shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, April 29th. Jefferies Group lowered their target price on shares of AMAG Pharmaceuticals from $58.00 to $45.00 and set a “buy” rating for the company in a report on Wednesday, August 10th. Deutsche Bank AG lowered their target price on shares of AMAG Pharmaceuticals from $42.00 to $35.00 and set a “hold” rating for the company in a report on Monday, May 9th. Finally, JPMorgan Chase & Co. restated a “hold” rating and issued a $37.00 target price on shares of AMAG Pharmaceuticals in a report on Thursday, May 5th. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $40.60.

The stock’s market capitalization is $899.27 million. The company has a 50-day moving average price of $25.71 and a 200 day moving average price of $23.86.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.25. During the same quarter in the prior year, the business earned $1.12 EPS. The firm had revenue of $127.40 million for the quarter, compared to analysts’ expectations of $128.52 million. The company’s revenue for the quarter was up 46.7% on a year-over-year basis. Analysts expect that AMAG Pharmaceuticals Inc. will post $5.47 earnings per share for the current year.

Several hedge funds have recently bought and sold shares of AMAG. Rhumbline Advisers raised its stake in AMAG Pharmaceuticals by 10.1% in the fourth quarter. Rhumbline Advisers now owns 37,447 shares of the specialty pharmaceutical company’s stock worth $1,131,000 after buying an additional 3,420 shares in the last quarter. Cornerstone Capital Management Holdings LLC. raised its stake in AMAG Pharmaceuticals by 570.4% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 49,608 shares of the specialty pharmaceutical company’s stock worth $1,498,000 after buying an additional 42,208 shares in the last quarter. Bank of Montreal Can raised its stake in AMAG Pharmaceuticals by 2,782.5% in the fourth quarter. Bank of Montreal Can now owns 75,781 shares of the specialty pharmaceutical company’s stock worth $2,287,000 after buying an additional 73,152 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in AMAG Pharmaceuticals by 13.9% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 176,100 shares of the specialty pharmaceutical company’s stock worth $5,316,000 after buying an additional 21,500 shares in the last quarter.

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.